Abstract
The CYP2D6 enzyme metabolizes tamoxifen to its active metabolite endoxifen. Earlier small studies have suggested that genotyping could categorize patients as extensive, intermediate, or poor metabolizers of tamoxifen. By extension, the hypothesis was that patients would derive different benefits from tamoxifen depending on their ability to metabolize it. However, multiple studies analyzing tumor tissue and clinical outcomes from large adjuvant endocrine trials have …
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
